Literature DB >> 11767964

Antimicrobial utilization and bacterial resistance at three different hospitals.

V Vlahović-Palcevski1, M Morović, G Palcevski, L Betica-Radić.   

Abstract

It has been generally recognized that the prevalence of bacterial resistance among bacteria is an unavoidable consequence of antibiotic use and is positively linked to the overall use of antibacterial drugs. The purpose of this study was to investigate the extent of antimicrobial usage and to evaluate the antimicrobial resistance at three different hospital settings in Croatia: a clinical hospital, a general hospital and a specialized clinic for infectious diseases. In this survey the antimicrobial drug consumption and antimicrobial susceptibility test results were analyzed for the first 6 months of 1997 in three different hospitals in Croatia: the University Hospital Center (UHC), Rijeka, the Clinic for Infectious Diseases 'Dr Fran Mihaljević', Zagreb and the Dubrovnik General Hospital. The data were collected from corresponding hospital pharmacy records and microbiology laboratories. Antimicrobial drug utilization was expressed in number of defined daily doses (DDDs) per 100 bed days. High antimicrobial utilization and high resistance rates were found in all three hospitals. At the Clinic for Infectious Diseases, the most frequently used antimicrobials where those of narrow spectrum while at the UHC Rijeka and the Dubrovnik General Hospital the broad spectrum antimicrobials were mostly used. The highest antimicrobial consumption was noted at the Susak locality of the UHC, Rijeka, where the highest resistance rates of bacteria to antimicrobials were also found. Results of this observational study indicate that attempts should be made to reduce the influence of factors that may lead to emergent resistance. The most effective approach to the prevention of transmission of multidrug-resistant pathogens is preventing the initial emergence of resistance. A rational and strict antibiotic policy is thus of great importance for the optimal use of these agents.

Entities:  

Mesh:

Year:  2001        PMID: 11767964     DOI: 10.1023/a:1012742314070

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  33 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

Review 2.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 3.  Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.

Authors:  M Michel; L Gutmann
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

4.  Trends in hospital antibiotic prescribing after introduction of an antibiotic policy.

Authors:  I M Gould; B Jappy
Journal:  J Antimicrob Chemother       Date:  1996-11       Impact factor: 5.790

5.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

6.  Antibiotic cost reduction by providing cost information.

Authors:  E Rubinstein; A Barzilai; S Segev; Y Samra; M Modan; O Dickerman; C Haklai
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Estimating worldwide current antibiotic usage: report of Task Force 1.

Authors:  N F Col; R W O'Connor
Journal:  Rev Infect Dis       Date:  1987 May-Jun

Review 8.  The value of new antimicrobial agents.

Authors:  J H Wagenvoort
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

9.  Hospital antibiotic control measures in the UK. Working Party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

10.  Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes.

Authors:  S L Pestotnik; D C Classen; R S Evans; J P Burke
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.